MS-N324 · Online mindfulness · Fear of recurrence · Survivorship · Human evidence · Appraised 13 November 2026

Can a self-directed nine-week online mindfulness program reduce moderate or severe fear of recurrence after breast, prostate or colorectal cancer?

Evidence at a glance

• Evidence label: Large randomized waitlist-controlled trial; modest sustained psychological benefit
• Benefit: Fear-of-recurrence, anxiety and depression scores improved at nine weeks and remained lower at nine months.
• Certainty: Moderate for self-reported psychological outcomes versus waitlist; less certain versus active therapy or diverse care settings.
• Risk: No serious program-specific physical risk is expected, but adverse events and deterioration pathways were not fully verified.

What was studied

MindOnLine unlocked one self-directed module weekly for nine weeks, combining education, mindfulness practice and meditation. The Australian trial randomized 434 adults within five years of stage I–III breast, prostate or colorectal cancer treatment or surveillance and with FCRI severity at least 13.

What the evidence found

At nine weeks, the between-group difference in total FCRI was −5.61 points (95% CI −8.61 to −2.61), anxiety −1.29 and depression −1.47. At nine months, differences remained −5.06 for FCRI, −1.22 for anxiety and −1.09 for depression. The clinical meaning of a roughly five-point total FCRI difference should be interpreted with the scale and individual baseline.

How to interpret it

The comparator was a waitlist, so attention, expectation and concurrent support may contribute. Seventy percent of participants were women and two thirds lived in metropolitan areas. The trial does not establish superiority to therapist-led care or benefit during active advanced cancer.

These outcomes concern symptoms, distress, sleep or supportive care. They do not establish tumor response, delayed recurrence, progression-free survival or longer overall survival.

Practical safety context

Fear of recurrence is common, but severe anxiety, depression, trauma symptoms, compulsive checking or suicidal thoughts deserve clinical care. Online mindfulness should not replace surveillance, diagnostic evaluation of new symptoms or evidence-based psychotherapy when indicated.

Questions for the care team

• Is my fear within the range studied and how will it be measured?
• Would self-directed mindfulness or therapist-led treatment fit my needs better?
• Who should I contact if the exercises intensify distress?

Funding and conflicts

The trial was funded by an Australian NHMRC partnership grant with partner contributions from the Victorian Department of Health, Epworth HealthCare and Western Health. Complete author conflict details were not re-extracted.

Sources

• Primary randomized trial (PMID 40756964)
• Open full text (PMCID PMC12318308)
• Publisher record and DOI 10.1016/j.eclinm.2025.103373

Last literature search: 13 November 2026. Record appraisal: 13 November 2026. The primary open report and abstract were appraised; the registry identifier was verified in the report. This page is educational and does not replace individualized medical advice.